Reducing the Immune Response to Immunotoxin
Open Access
- 1 January 2004
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 10 (1) , 13-15
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- Pretreatment with Rituximab Does Not Inhibit the Human Immune Response against the Immunogenic Protein LMB-1Clinical Cancer Research, 2004
- Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphomaEuropean Journal of Cancer, 2001
- Antibody Response to DT–GM, a Novel Fusion Toxin Consisting of a Truncated Diphtheria Toxin (DT) Linked to Human Granulocyte–Macrophage Colony Stimulating Factor (GM), during a Phase I Trial of Patients with Relapsed or Refractory Acute Myeloid LeukemiaClinical Immunology, 2001
- Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicityProceedings of the National Academy of Sciences, 2000
- TARGETING ACTIVATED LYMPHOCYTES WITH AN ENTIRELY HUMAN IMMUNOTOXIN ANALOGUE: HUMAN PANCREATIC RNASE1-HUMAN IL-2 FUSIONCytokine, 2000
- Phase I/II Study of Murine Monoclonal Antibody-Ricin A Chain (XOMAZYME-Mel) Immunoconjugate plus Cyclosporine A in Patients with Metastatic MelanomaJournal of Immunotherapy, 1993
- Rational immunotherapy with ribonuclease chimerasCell Biochemistry and Biophysics, 1992
- Humanization of immunotoxins.Proceedings of the National Academy of Sciences, 1992
- An anti‐CD5 immunotoxin for chronic lymphocytic leukemia: Enhancement of cytotoxicity with human serum albumin‐monensinInternational Journal of Cancer, 1989
- Humoral Immune Response to a Ricin A Chain Immunotoxin in Patients with Metastatic MelanomaCancer Drug Delivery, 1987